BridgeBio Oncology appoints CSO Pedro Beltran as CEO, makes Neil Kumar executive chairman
read at Endpoints ↗Neutral
BridgeBio Oncology Therapeutics announced a leadership reshuffle aimed at strengthening its focus on KRAS-driven cancer programs.
The company is replacing CEO Eli Wallace with its chief scientific officer, Pedro Beltran, who will now serve as chief executive officer.
Board member Neil Kumar will assume the role of executive chairman, and the changes are intended to accelerate the spinoff’s KRAS work amid growing competition in the oncology space.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “BridgeBio’s oncology spinoff swaps out CEOs as it seeks to accelerate KRAS work”
read at Endpoints ↗99 words · retrieved Apr 26
comments(0)
5-min edit window · permanent after that